Aggressive breast cancer is an invasive form with a differentiation degree G3/G4, the absence of estrogen receptor and progesterone and the absence or presence of the gene HER 2(+ or 3+). The immunohistochemical tests have an important role in establishing the diagnosis and the therapy.

Material and method: It was shown that the aggressive breast cancers, 97 out of 316 cases were operated in the period October 2011 – February 2014. The criteria of inclusion/ exclusion in the study groups and the treatment schemes were exposed.

Results: For the study group (group A=43/ group B=45/ group C=9 cases), the distribution according to the age group and immunohistochemical classification, were shown and, histologically, the type of surgical intervention, postoperative staging, postoperative complications were highlighted.

Conclusions: The treatment of the aggressive forms of breast cancer, neoadjuvant and adjuvant can both be set only by IHC tests.